Abstract | PURPOSE: PATIENTS AND METHODS: Eligibility criteria included Karnofsky performance status > or = 60%, locally advanced or metastatic pancreatic adenocarcinoma, and no prior chemotherapy. Radiation alone for locally advanced disease was permitted. Patients were randomly assigned on a 1:1 basis. For the exatecan plus gemcitabine arm, exatecan 2.0 mg/m2 and gemcitabine 1,000 mg/m2 were administered on days 1 and 8, every 3 weeks. Gemcitabine alone was dosed at 1,000 mg/m2 up to 7 weeks in the first cycle, then once a week for the first 3 weeks of a 4-week cycle. Tumor assessment was performed every 6 weeks. The primary end point was overall survival. An intent-to-treat analysis was used. RESULTS: CONCLUSION:
|
Authors | Ghassan K Abou-Alfa, Richard Letourneau, Graydon Harker, Manuel Modiano, Herbert Hurwitz, Nerses Simon Tchekmedyian, Kevie Feit, Judie Ackerman, Robert L De Jager, S Gail Eckhardt, Eileen M O'Reilly |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 24
Issue 27
Pg. 4441-7
(Sep 20 2006)
ISSN: 1527-7755 [Electronic] United States |
PMID | 16983112
(Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antimetabolites, Antineoplastic
- Antineoplastic Agents, Phytogenic
- Deoxycytidine
- exatecan
- Camptothecin
- Gemcitabine
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antimetabolites, Antineoplastic
(administration & dosage, therapeutic use)
- Antineoplastic Agents, Phytogenic
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Camptothecin
(administration & dosage, analogs & derivatives)
- Deoxycytidine
(administration & dosage, analogs & derivatives, therapeutic use)
- Disease-Free Survival
- Drug Administration Schedule
- Female
- Humans
- Male
- Middle Aged
- Pancreatic Neoplasms
(drug therapy, pathology)
- Survival Analysis
- Treatment Outcome
- Gemcitabine
|